Year-end Sale % OFF 
Abstract
Abstract: F-18 FDG PET scans acquired after insulin administration usually show prominent skeletal and cardiac muscle FDG uptake, which may hinder accurate scan interpretation. We performed an FDG PET/CT scan on a 25-year-old diabetic woman who received the long-acting insulin analog glargine (Lantus; Sanofi-Aventis) 3 hours before FDG injection. The scan showed no significant alteration of FDG biodistribution. Insulin glargine has no pronounced peak over 24 hours and is being used more frequently to create basal insulin level in patients with type 1 and type 2 diabetes. Our findings suggest that insulin glargine may not need to be withheld prior to PET scintigraphy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
